CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 952 enrolled
Drug / intervention
MK0826, ertapenem sodium +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00090272
NCT00090272Phase 3Completed

A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Ertapenem Sodium (MK0826) Versus Cefotetan for the Prophylaxis of Surgical Site Infection Following Elective Colorectal Surgery

Merck Sharp & Dohme LLC·interventional·Posted Aug 27, 2004·Updated Feb 17, 2017

In Brief

A Phase 3 clinical trial evaluating MK0826, ertapenem sodium and Comparator: cefotetan for Colorectal Surgery. Completed, enrolled 952 participants.

Detailed Summary

The objective of this study is to evaluate the safety and efficacy of a one time dose of an intravenous marketed drug being evaluated for a new indication as compared to a marketed drug already approved for the prevention of surgical site infection following colorectal surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 27, 2004
Enrollment StartApr 1, 2002
Primary CompletionMar 1, 2005
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 21.8 years ago

Interventions

MK0826, ertapenem sodiumdrug

Comparator: cefotetandrug